231 related articles for article (PubMed ID: 28968794)
1. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
Torresi J; Richmond PC; Heron LG; Qiao M; Marjason J; Starr-Spires L; van der Vliet D; Jin J; Wartel TA; Bouckenooghe A
J Infect Dis; 2017 Oct; 216(7):834-841. PubMed ID: 28968794
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Dayan GH; Thakur M; Boaz M; Johnson C
Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
[TBL] [Abstract][Full Text] [Related]
6. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
8. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
Ravel G; Mantel N; Silvano J; Rogue A; Guy B; Jackson N; Burdin N
Vaccine; 2017 Oct; 35(43):5918-5923. PubMed ID: 28882438
[TBL] [Abstract][Full Text] [Related]
10. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
11. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
[TBL] [Abstract][Full Text] [Related]
14. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
Morrison D; Legg TJ; Billings CW; Forrat R; Yoksan S; Lang J
J Infect Dis; 2010 Feb; 201(3):370-7. PubMed ID: 20059357
[TBL] [Abstract][Full Text] [Related]
15. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
[TBL] [Abstract][Full Text] [Related]
18. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
19. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
[TBL] [Abstract][Full Text] [Related]
20. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]